AdKCNH2-G628S
Phase 1Biologic
AdKCNH2-G628S is one of 15 biologic programs targeting Post-Operative Atrial Fibrillation. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Post-Operative Atrial Fibrillation
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Colcrys
Alnylam PharmaceuticalsPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Aldactone
PfizerPhase 3
Cordarone
WWyeth-Lederle Vaccines
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Coumadin
AAbbott
Phase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Vernakalant
AAdvanz Pharma
Phase 3
Botox
RRevance Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AdKCNH2-G628S. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details